POLITICO @politico
The Biden administration’s contentious decision to only partially cover Aduhelm could reach well beyond the world of Alzheimer’s drugs, potentially affecting efforts to develop treatments for devastating diseases https://t.co/NKZZ17kuqF — PolitiTweet.org